Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model
Behavioural Brain Research · 2025
DOI: 10.1016/j.bbr.2024.115270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Behavioural Brain Research, 2025. Verfasst von Ronnita C Sequeira und 1 weiteren Autor:innen. Beteiligte Einrichtung: SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Gate No.1, Mithibai College Campus, Vaikunthlal Mehta Rd, Vile Parle West, Mumbai, Maharashtra 4000…. Hauptthemen laut MEDLINE: Alzheimer Disease, Aluminum Chloride, Famotidine, Disease Models, Animal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD), a chronic neurodegenerative disease, presents a substantial global health challenge. This study explored the potential therapeutic role of famotidine, a histamine (H2) receptor antagonist, as a glycogen synthase kinase-3β (GSK-3β) inhibitor in the context of AD induced by aluminium chloride (AlCl3) in a rat model. The intricate relationship between GSK-3β dysregulation and AD pathogenesis, particularly in amyloid-β (Aβ) production, formed the basis for investigating famotidine's efficacy. Molecular modelling revealed famotidine's efficient binding to GSK-3β, suggesting inhibitory potential. In behavioural assessments, famotidine-treated groups exhibited dose-dependent improvements in Morris Water Maze, Novel Object Recognition, and Y-Maze tests, comparable to the standard Rivastigmine tartrate group. Biochemical analyses showed that famotidine inhibits acetylcholinesterase, decreases lipid peroxidation, increases antioxidant activity, and mitigates oxidative stress. Moreover, famotidine significantly lowered the levels of GSK-3β, IL-6, and Aβ(1-42). The neuroprotective effects of famotidine were further supported by histopathological analysis. This comprehensive investigation underscores famotidine's potential as a GSK-3β inhibitor, providing insights into its therapeutic impact on AD induced by AlCl3. The study offers a promising avenue for repurposing famotidine due to its established safety profile and widespread availability, highlighting its potential in addressing the formidable challenge of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Gate No.1, Mithibai College Campus, Vaikunthlal Mehta Rd, Vile Parle West, Mumbai, Maharashtra 400056, India.
- SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Gate No.1, Mithibai College Campus, Vaikunthlal Mehta Rd, Vile Parle West, Mumbai, Maharashtra 400056, India; Department of Pharmaceutical Sciences and Technology, Insti…
Förderung
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Sequeira, R. C., & Godad, A. (2025). Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2024.115270
Vancouver
Sequeira RC, Godad A. Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model. Behavioural Brain Research. 2025. doi:10.1016/j.bbr.2024.115270
BibTeX
@article{Sequeira2025,
author = {Sequeira, Ronnita C and Godad, Angel},
title = {Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model},
journal = {Behavioural Brain Research},
year = {2025},
doi = {10.1016/j.bbr.2024.115270}
}
EUVIMED